ロード中...
Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
The advent of Adcetris™ and Kadcyla™, two recently FDA-approved antibody–drug conjugates (ADCs), in the clinic has had a major impact on the treatment of lymphoma and breast cancer patients, respectively, worldwide. Despite these successes many new ADCs fail at various stages of development, often d...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Royal Society of Chemistry
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4159697/ https://ncbi.nlm.nih.gov/pubmed/25103319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c4ob01550a |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|